MCID: VRR004
MIFTS: 54

Verrucous Carcinoma malady

Categories: Cancer diseases

Aliases & Classifications for Verrucous Carcinoma

Aliases & Descriptions for Verrucous Carcinoma:

Name: Verrucous Carcinoma 12 14 69
Verrucous Squamous Cell Carcinoma 12
Verrucous Squamous Carcinoma 12
Verrucous Carcinoma Nos 12
Condylomatous Carcinoma 69
Carcinoma, Verrucous 42
Carcinoma Verrucous 52
Warty Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3737
MeSH 42 D018289
NCIt 47 C3781
UMLS 69 C0206706

Summaries for Verrucous Carcinoma

Disease Ontology : 12 A squamous cell carcinoma that is a diffuse, papillary, non metastasizing, well differentiated, malignant neoplasm of epidermis or oral epithelium.

MalaCards based summary : Verrucous Carcinoma, also known as verrucous squamous cell carcinoma, is related to urethral verrucous carcinoma and cervical verrucous carcinoma. An important gene associated with Verrucous Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Cetuximab and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include cervix, skin and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and cellular

Wikipedia : 71 Verrucous carcinoma (VC) is an uncommon variant of squamous cell carcinoma. This form of cancer is often... more...

Related Diseases for Verrucous Carcinoma

Diseases related to Verrucous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 188)
id Related Disease Score Top Affiliating Genes
1 urethral verrucous carcinoma 32.9 CDKN2A TP53
2 cervical verrucous carcinoma 31.3 CCND1 CDKN1A CDKN2A KRT10 MDM2 MIR125A
3 osteomyelitis 30.0 MDM2 RB1
4 larynx verrucous carcinoma 11.9
5 glottis verrucous carcinoma 11.9
6 subglottis verrucous carcinoma 11.9
7 supraglottis verrucous carcinoma 11.9
8 esophagus verrucous carcinoma 11.9
9 vulva verrucous carcinoma 11.9
10 penis non-invasive verrucous carcinoma 11.9
11 penis verrucous carcinoma 11.8
12 bladder verrucous squamous cell carcinoma 10.8
13 anal buschke-lowenstein tumor 10.8
14 squamous cell carcinoma 10.3
15 clear cell adenofibroma 10.3 CDKN2A TP53
16 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
17 pericardium leiomyoma 10.3 CDKN2A TP53
18 spondylarthropathy 10.3 CDKN2A TP53
19 rommen mueller sybert syndrome 10.3 MDM2 TP53
20 bone squamous cell carcinoma 10.3 CDKN2A RB1
21 lacrimal gland squamous cell carcinoma 10.3 CDKN2A TP53
22 functionless pituitary adenoma 10.2 MDM2 TP53
23 ampulla of vater neoplasm 10.2 CDKN2A TP53
24 coccidiosis 10.2 CDKN2A TP53
25 postpoliomyelitis syndrome 10.2 CDKN2A TP53
26 paraphimosis 10.2 CDKN2A TP53
27 anal carcinoma in situ 10.2 CDKN2A TP53
28 aortic aneurysm 10.2 CDKN2A MDM2
29 skeletal tuberculosis 10.2 CCND1 CDKN2A
30 uterine disease 10.2 CDKN2A TP53
31 adult central nervous system mature teratoma 10.2 CCND1 TP53
32 fragile x-associated tremor/ataxia syndrome 10.2 CDKN2A TP53
33 spastic ataxia 5 10.2 CDKN2A TP53
34 villoglandular endometrial endometrioid adenocarcinoma 10.2 CCND1 TP53
35 coronary stenosis 10.2 MDM2 TP53
36 gallbladder pleomorphic giant cell adenocarcinoma 10.2 CDKN2A TP53
37 brachydactyly tibial hypoplasia 10.2 CCND1 CDKN2A
38 adult epithelioid sarcoma 10.2 CDKN2A TP53
39 decubitus ulcer 10.2 CCND1 CDKN2A
40 anal neuroendocrine tumor 10.2 CCND1 CDKN2A
41 mediastinum liposarcoma 10.2 CDKN2A MDM2
42 active vestibular meniere's disease 10.2 CCND1 CDKN2A
43 uterine cervix leukoplakia 10.2 CDKN2A TP53
44 brain stem angioblastoma 10.2 MDM2 TP53
45 breast epithelioid hemangioma 10.2 CDKN1A TP53
46 inverted follicular keratosis 10.2 CDKN1A TP53
47 childhood brain stem glioma 10.2 CCND1 TP53
48 perineural angioma 10.1 CDKN1A TP53
49 endodermal sinus tumor 10.1 MDM2 TP53
50 endometrial squamous cell carcinoma 10.1 CDKN2A MDM2 TP53

Graphical network of the top 20 diseases related to Verrucous Carcinoma:



Diseases related to Verrucous Carcinoma

Symptoms & Phenotypes for Verrucous Carcinoma

GenomeRNAi Phenotypes related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 CDKN1A CDKN2A RB1 TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 CCND1 CDKN1A CDKN2A RB1 TP53

MGI Mouse Phenotypes related to Verrucous Carcinoma:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.09 CCND1 CDKN1A CDKN2A MDM2 RB1 TP53
2 immune system MP:0005387 10.04 RB1 TP53 TYMP CCND1 CDKN1A CDKN2A
3 cardiovascular system MP:0005385 10.03 CCND1 CDKN1A CDKN2A MDM2 RB1 TP53
4 digestive/alimentary MP:0005381 10 CCND1 CDKN1A CDKN2A MDM2 RB1 TP53
5 endocrine/exocrine gland MP:0005379 9.99 CCND1 CDKN1A CDKN2A MDM2 RB1 TP53
6 integument MP:0010771 9.95 CCND1 CDKN1A CDKN2A MDM2 RB1 TP53
7 craniofacial MP:0005382 9.93 CCND1 CDKN1A MDM2 RB1 TP53
8 nervous system MP:0003631 9.91 CCND1 CDKN1A CDKN2A MDM2 RB1 TP53
9 neoplasm MP:0002006 9.88 CCND1 CDKN1A CDKN2A MDM2 RB1 TP53
10 liver/biliary system MP:0005370 9.85 CDKN1A CDKN2A MDM2 RB1 TP53
11 muscle MP:0005369 9.83 CDKN1A CDKN2A MDM2 RB1 TP53
12 no phenotypic analysis MP:0003012 9.72 RB1 TP53 CDKN1A CDKN2A MDM2
13 reproductive system MP:0005389 9.63 CCND1 CDKN1A CDKN2A MDM2 RB1 TP53
14 pigmentation MP:0001186 9.56 CDKN2A MDM2 RB1 TP53
15 respiratory system MP:0005388 9.35 CCND1 CDKN1A CDKN2A RB1 TP53
16 skeleton MP:0005390 9.17 RB1 TP53 TYMP CCND1 CDKN1A CDKN2A

Drugs & Therapeutics for Verrucous Carcinoma

Drugs for Verrucous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
3
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
4
Bleomycin Approved Phase 3 11056-06-7 5360373
5
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
6
Levoleucovorin Approved Phase 3 68538-85-2
7
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
8
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10
Fluconazole Approved Phase 2, Phase 3 86386-73-4 3365
11
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
12
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
13
Megestrol acetate Approved, Vet_approved Phase 3 595-33-5 11683
14
Bevacizumab Approved, Investigational Phase 3,Phase 1,Phase 2 216974-75-3
15
Succinylcholine Approved Phase 3,Phase 2 306-40-1 5314
16
Doxepin Approved Phase 3 1668-19-5 667477 667468
17
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
19
leucovorin Approved, Nutraceutical Phase 3,Phase 1,Phase 2 58-05-9 54575, 6560146 143
20
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
21 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
22 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
23 Antimetabolites Phase 3,Phase 2,Phase 1
24 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
25 Antimitotic Agents Phase 3,Phase 2,Phase 1
26 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
27 Antirheumatic Agents Phase 3
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
29 Liver Extracts Phase 3,Phase 2,Phase 1
30 Peripheral Nervous System Agents Phase 3,Phase 2
31 Anti-Infective Agents Phase 2, Phase 3,Phase 1
32 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
33 Autonomic Agents Phase 3,Phase 2
34 Neurotransmitter Agents Phase 3,Phase 2
35 Antidotes Phase 3
36 Calcium, Dietary Phase 3
37
Cobalt Phase 3 7440-48-4 104729
38 Dermatologic Agents Phase 3,Phase 2,Phase 1
39 Folic Acid Antagonists Phase 3,Phase 1,Phase 2
40 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1,Phase 2
41 Protective Agents Phase 3,Phase 2
42 Vitamin B Complex Phase 3,Phase 2,Phase 1
43 Adjuvants, Anesthesia Phase 3
44 Analgesics Phase 3
45 Analgesics, Opioid Phase 3
46 Anesthetics Phase 3
47 Anesthetics, General Phase 3
48 Anesthetics, Intravenous Phase 3
49 Central Nervous System Depressants Phase 3
50 Narcotics Phase 3

Interventional clinical trials:

(show top 50) (show all 142)
id Name Status NCT ID Phase
1 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3
3 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
5 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3
6 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3
7 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
8 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3
9 Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Recruiting NCT00956007 Phase 3
10 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3
11 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3
12 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Active, not recruiting NCT00820248 Phase 3
13 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Active, not recruiting NCT01156142 Phase 3
14 CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy Active, not recruiting NCT01545687 Phase 3
15 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3
16 Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer Unknown status NCT00003489 Phase 2
17 Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00833261 Phase 2
18 Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00022217 Phase 2
19 Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Unknown status NCT00625937 Phase 2
20 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
21 Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Completed NCT02007200 Phase 2
22 Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Completed NCT00458978 Phase 2
23 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Completed NCT01256385 Phase 2
24 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00103259 Phase 2
25 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2
26 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2
27 Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00513435 Phase 2
28 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2
29 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2
30 SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00095628 Phase 2
31 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2
32 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2
33 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2
34 Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck Completed NCT00720304 Phase 2
35 Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery Completed NCT00738868 Phase 2
36 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2
37 Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00639769 Phase 2
38 High-dose ICE With Amifostine Completed NCT00003657 Phase 2
39 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2
40 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2
41 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer Completed NCT00004901 Phase 1, Phase 2
42 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2
43 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2
44 Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery Completed NCT01333085 Phase 1, Phase 2
45 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2
46 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2
47 Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions Recruiting NCT01414426 Phase 2
48 Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery Recruiting NCT02734537 Phase 2
49 Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity Recruiting NCT02295540 Phase 1, Phase 2
50 Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Active, not recruiting NCT02035527 Phase 1, Phase 2

Search NIH Clinical Center for Verrucous Carcinoma

Cochrane evidence based reviews: carcinoma, verrucous

Genetic Tests for Verrucous Carcinoma

Anatomical Context for Verrucous Carcinoma

MalaCards organs/tissues related to Verrucous Carcinoma:

39
Cervix, Skin, Bone, T Cells, Tongue, Neutrophil, Lymph Node

Publications for Verrucous Carcinoma

Articles related to Verrucous Carcinoma:

(show top 50) (show all 566)
id Title Authors Year
1
A clitoral verrucous carcinoma in an area of lichen planus has aggressive features. ( 28061900 )
2017
2
Diagnostic Biomarkers in Oral Verrucous Carcinoma: A Systematic Review. ( 27924463 )
2017
3
Pyoderma Vegetans Misdiagnosed as Verrucous Carcinoma. ( 26825160 )
2016
4
Verrucous Carcinoma of the Esophagus. ( 27803424 )
2016
5
Investigation of the association between miRa89181b, Bcla892 and LRIG1 in oral verrucous carcinoma. ( 27509922 )
2016
6
Anal verrucous carcinoma is not related to infection with human papillomaviruses and should be distinguished from giant condyloma (Buschke-LAPwenstein tumor). ( 28012208 )
2016
7
Endoscopic submucosal dissection for an atypical small verrucous carcinoma: a case report. ( 27036299 )
2016
8
Laryngeal Verrucous Carcinoma: A Systematic Review. ( 27484231 )
2016
9
Bilateral Plantar Verrucous Carcinoma. ( 28035248 )
2016
10
An Unusual Presentation of Verrucous Carcinoma of the Foot with Bone Invasion. ( 28033059 )
2016
11
Subungual Verrucous Carcinoma of the Right Little Finger with Underlying Bony Invasion. ( 27746655 )
2016
12
Intraosseous verrucous carcinoma arising from an orthokeratinized odontogenic keratocyst: A report of a rarest entity. ( 27630514 )
2016
13
Reconstruction of the Auricular Defect After Excision of Verrucous Carcinoma. ( 26674896 )
2016
14
Verrucous carcinoma-an enigma: Case report and review. ( 27630507 )
2016
15
Oral verrucous carcinoma: A retrospective analysis for clinicopathologic features. ( 27072227 )
2016
16
Antioxidant enzymes in oral verrucous carcinoma. ( 27245640 )
2016
17
Verrucous Carcinoma of the Vulva: A 20 Year Retrospective Study and Literature Review. ( 26704335 )
2016
18
Verrucous carcinoma arising in a port wine stain. ( 26809361 )
2016
19
Oral verrucous carcinoma: From multifactorial etiology to diverse treatment regimens (Review). ( 27121637 )
2016
20
Verrucous Carcinoma of the Vulva: A Case Report and Review of the Literature. ( 26904547 )
2016
21
Verrucous Carcinoma of the Eyelid. ( 27478359 )
2016
22
Recurrent verrucous carcinoma of the urinary bladder after transurethral resection followed by intravesical mitomycin, and a review of the literature. ( 27307433 )
2016
23
The Akt/mTOR pathway is activated in verrucous carcinoma of the oral cavity. ( 26775690 )
2016
24
Oral verrucous hyperplasia versus oral verrucous carcinoma: A clinicopathologic dilemma revisited using p53 as immunohistochemical marker. ( 27721598 )
2016
25
A Case of Squamous Cell Carcinoma in the External Auditory Canal Previously Treated for Verrucous Carcinoma. ( 27942606 )
2016
26
Verrucous carcinoma on the lower extremities. ( 26367757 )
2015
27
Diagnosis and treatment of penile verrucous carcinoma. ( 25789024 )
2015
28
Laryngeal Verrucous Carcinoma: A Population-Based Analysis. ( 26124268 )
2015
29
Angiogenesis, Proliferative Activity and DNA Ploidy in Oral Verrucous Carcinoma: A Comparative Study Including Verrucous Hyperplasia and Squamous Cell Carcinoma. ( 26156885 )
2015
30
Verrucous Carcinoma on the Dorsal Aspect of the Hand. ( 26156648 )
2015
31
Cutaneous leishmaniasis mimicking verrucous carcinoma: A case with an unusual clinical course. ( 25994897 )
2015
32
VERRUCOUS CARCINOMA OF THE ESOPHAGUS INVOLVING THE ENTIRE ESOPHAGUS. ( 26734805 )
2015
33
Intraosseous verrucous carcinoma arising from an infected dentigerous cyst-A case report. ( 26254175 )
2015
34
Inverted verrucous carcinoma of the buttock mimicking abscess and gossypiboma: MR and pathologic correlation. ( 25957256 )
2015
35
Verrucous carcinoma on a chronic sacral pressure ulcer in a patient with meningomyelocele. Case report and review of the literature. ( 25661446 )
2015
36
Reliability of Incision Biopsy for Diagnosis of Oral Verrucous Carcinoma: A Multivariate Clinicopathological Study. ( 26225050 )
2015
37
Verrucous carcinoma developing in a long standing case of ulcerative lichen planus of sole: a rare case report. ( 25756157 )
2015
38
Human Papillomavirus in Oral Leukoplakia, Verrucous Carcinoma, Squamous Cell Carcinoma, and Normal Mucous Membrane. ( 26674929 )
2015
39
Oral verrucous carcinoma and ameloblastoma: a rare coincidence. ( 25938088 )
2015
40
Expression of Matrix Metalloproteinase-10 at Invasive Front of Squamous Cell Carcinoma and Verrucous Carcinoma in the Oral Cavity. ( 26434883 )
2015
41
Necessity of Distinguishing Verrucous Carcinoma From Verrucous Skin Lesion Overlaying Residual Skin Staples in an Area of Sensory Loss: A Case Report. ( 26171095 )
2015
42
GLUT-1 immunoexpression in oral epithelial dysplasia, oral squamous cell carcinoma, and verrucous carcinoma. ( 26062860 )
2015
43
Expression of Cell Cycle-associated Proteins p53, pRb, p16, p27, and Correlation With Survival: A Comparative Study on Oral Squamous Cell Carcinoma and Verrucous Carcinoma. ( 26447892 )
2015
44
Immunohistochemical findings and differential diagnosis of papillary-type cutaneous verrucous carcinoma of the neck: A case report. ( 26788215 )
2015
45
Multi Centricity of Oral Verrucous Carcinoma: A Case Series of 22 Cases. ( 26075168 )
2015
46
What is your diagnosis? verrucous carcinoma. ( 26367754 )
2015
47
A rare case of verrucous carcinoma of penis in an human immunodeficiency virus- infected patient. ( 26692616 )
2015
48
Association of Macrophages With Angiogenesis in Oral Epithelial Dysplasia, Oral Verrucous Carcinoma, and Oral Squamous Cell Carcinoma: An Immunohistochemical Study. ( 26657870 )
2015
49
Verrucous Carcinoma with Oral Submucous Fibrosis: A Rare Case with Brief Review. ( 26468468 )
2015
50
Verrucous carcinoma and squamous cell papilloma of the oral cavity: Report of two cases and review of literature. ( 26430380 )
2015

Variations for Verrucous Carcinoma

Expression for Verrucous Carcinoma

Search GEO for disease gene expression data for Verrucous Carcinoma.

Pathways for Verrucous Carcinoma

Pathways related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.74 CCND1 CDKN1A CDKN2A MDM2 RB1 TP53
2
Show member pathways
13.61 CCND1 CDKN1A CDKN2A MDM2 RB1 TP53
3
Show member pathways
13.34 CCND1 CDKN1A CDKN2A MDM2 RB1 TP53
4
Show member pathways
13.29 CCND1 CDKN1A MDM2 TP53 TYMP
5
Show member pathways
13.06 CDKN1A CDKN2A MDM2 RB1 TP53
6
Show member pathways
12.97 CCND1 CDKN1A CDKN2A MDM2 RB1 TP53
7
Show member pathways
12.87 CDKN1A CDKN2A MDM2 TP53
8
Show member pathways
12.82 CCND1 CDKN1A RB1 TP53
9
Show member pathways
12.74 CDKN1A CDKN2A MDM2 TP53
10 12.66 CCND1 CDKN1A CDKN2A MDM2 RB1 TP53
11
Show member pathways
12.64 CCND1 CDKN1A MDM2 RB1 TP53
12 12.55 CCND1 CDKN1A MDM2 TP53
13
Show member pathways
12.54 CCND1 CDKN1A CDKN2A MDM2 RB1 TP53
14
Show member pathways
12.51 CCND1 MDM2 RB1 TP53
15 12.49 CCND1 CDKN1A CDKN2A MDM2 MIR125A TP53
16 12.45 CCND1 CDKN1A CDKN2A MDM2 RB1 TP53
17 12.43 CCND1 CDKN1A CDKN2A RB1 TP53
18
Show member pathways
12.38 CCND1 CDKN1A MDM2 TP53
19
Show member pathways
12.36 CCND1 CDKN1A CDKN2A RB1 TP53
20
Show member pathways
12.34 CCND1 CDKN1A MDM2 TP53
21
Show member pathways
12.29 CCND1 CDKN1A MDM2 TP53
22 12.28 CDKN1A MDM2 RB1 TP53
23
Show member pathways
12.28 CCND1 CDKN1A MDM2 RB1 TP53
24
Show member pathways
12.27 CDKN1A RB1 TP53
25 12.27 CCND1 CDKN1A MDM2 TP53
26
Show member pathways
12.24 CCND1 CDKN1A CDKN2A MDM2 RB1 TP53
27
Show member pathways
12.21 CCND1 CDKN1A CDKN2A RB1
28 12.21 CCND1 CDKN1A CDKN2A MDM2 RB1 TP53
29
Show member pathways
12.2 CCND1 CDKN1A MDM2 RB1 TP53
30 12.17 CDKN1A MDM2 TP53
31 12.15 CCND1 MDM2 RB1 TP53
32 12.13 CCND1 CDKN1A TP53
33 12.1 CCND1 CDKN1A MDM2 TP53
34 12.1 CCND1 CDKN1A CDKN2A MDM2 RB1 TP53
35 12.09 CCND1 CDKN1A CDKN2A MDM2 TP53
36
Show member pathways
12.07 CCND1 CDKN1A MDM2
37 12.06 CDKN1A MDM2 RB1 TP53
38
Show member pathways
12.04 CCND1 CDKN1A MDM2
39 12.03 CCND1 CDKN1A TP53
40 11.98 CCND1 RB1 TP53
41 11.98 CCND1 CDKN1A CDKN2A MDM2 TP53
42 11.96 CCND1 MDM2 TP53
43 11.95 CCND1 CDKN1A TP53
44 11.92 CDKN1A CDKN2A MDM2 RB1 TP53
45 11.89 CCND1 CDKN1A MDM2 RB1
46
Show member pathways
11.83 CDKN1A MDM2 TP53
47 11.8 CCND1 RB1 TP53
48 11.79 CDKN1A MDM2 TP53
49 11.78 CDKN1A CDKN2A MDM2 TP53
50 11.78 CCND1 CDKN1A MDM2 RB1 TP53

GO Terms for Verrucous Carcinoma

Cellular components related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein kinase holoenzyme complex GO:0000307 8.62 CCND1 CDKN1A

Biological processes related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

(show all 35)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.97 CCND1 MDM2 RB1 TP53
2 negative regulation of transcription, DNA-templated GO:0045892 9.9 CDKN2A MDM2 RB1 TP53
3 cell cycle GO:0007049 9.88 CCND1 CDKN1A CDKN2A RB1 TP53
4 negative regulation of cell proliferation GO:0008285 9.84 CDKN1A CDKN2A RB1 TP53
5 negative regulation of gene expression GO:0010629 9.79 CDKN1A MDM2 RB1
6 regulation of cell cycle GO:0051726 9.72 CCND1 CDKN1A RB1
7 negative regulation of cell growth GO:0030308 9.7 CDKN1A CDKN2A TP53
8 cell cycle arrest GO:0007050 9.67 CDKN1A CDKN2A RB1 TP53
9 response to organonitrogen compound GO:0010243 9.66 CCND1 CDKN1A
10 response to steroid hormone GO:0048545 9.66 CCND1 MDM2
11 cellular response to organic substance GO:0071310 9.65 CCND1 MDM2
12 response to antibiotic GO:0046677 9.65 MDM2 TP53
13 positive regulation of reactive oxygen species metabolic process GO:2000379 9.65 CDKN1A TP53
14 cellular response to ionizing radiation GO:0071479 9.64 CDKN1A TP53
15 intrinsic apoptotic signaling pathway GO:0097193 9.64 CDKN1A TP53
16 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.63 CDKN1A TP53
17 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.63 CDKN1A RB1
18 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.62 CDKN1A CDKN2A
19 cellular senescence GO:0090398 9.62 CDKN1A CDKN2A
20 negative regulation of cell cycle arrest GO:0071157 9.61 CCND1 MDM2
21 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.61 CDKN1A MDM2 TP53
22 negative regulation of phosphorylation GO:0042326 9.59 CDKN1A CDKN2A
23 positive regulation of protein export from nucleus GO:0046827 9.58 MDM2 TP53
24 response to iron ion GO:0010039 9.58 CCND1 MDM2
25 response to corticosterone GO:0051412 9.57 CCND1 CDKN1A
26 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.56 CDKN1A TP53
27 response to magnesium ion GO:0032026 9.51 CCND1 MDM2
28 cellular response to gamma radiation GO:0071480 9.5 CDKN1A MDM2 TP53
29 mitotic G1 DNA damage checkpoint GO:0031571 9.49 CCND1 TP53
30 signal transduction by p53 class mediator GO:0072331 9.46 CDKN1A TP53
31 G1/S transition of mitotic cell cycle GO:0000082 9.46 CCND1 CDKN1A CDKN2A RB1
32 response to X-ray GO:0010165 9.43 CCND1 CDKN1A TP53
33 cellular response to actinomycin D GO:0072717 9.4 MDM2 TP53
34 replicative senescence GO:0090399 9.13 CDKN1A CDKN2A TP53
35 Ras protein signal transduction GO:0007265 8.92 CDKN1A CDKN2A RB1 TP53

Molecular functions related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.67 CCND1 CDKN1A CDKN2A TP53
2 enzyme binding GO:0019899 9.56 CCND1 MDM2 RB1 TP53
3 transcription factor binding GO:0008134 9.46 CCND1 CDKN2A RB1 TP53
4 cyclin-dependent protein serine/threonine kinase activity GO:0004693 9.43 CCND1 CDKN1A
5 SUMO transferase activity GO:0019789 9.4 CDKN2A MDM2
6 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.32 CDKN1A CDKN2A
7 ubiquitin protein ligase binding GO:0031625 9.26 CDKN1A MDM2 RB1 TP53
8 disordered domain specific binding GO:0097718 8.8 MDM2 RB1 TP53

Sources for Verrucous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....